A randomized, double-blind, placebo-controlled, dual-center clinical study to evaluate the efficacy and safety of pitavastatin calcium dispersible tablets in the treatment of active systemic lupus erythematosus

开始日期2024-10-31

申办/合作机构-

CTR20242862

/ TerminatedN/A

匹伐他汀钙片在健康受试者中的单剂量、随机、开放、交叉、两制剂、两周期空腹和餐后人体生物等效性试验

主要目的：以四川赛卓药业股份有限公司的匹伐他汀钙片（规格：2mg）为受试制剂，以Kowa Company,Ltd.的匹伐他汀钙片（商品名：力清之®（LIVALO KOWA ®），规格：2mg）为参比制剂，按生物等效性试验的有关规定，考察两制剂在健康人体内的生物等效性。次要目的：观察受试制剂和参比制剂在健康受试者中的安全性。

开始日期2024-08-01

申办/合作机构

四川赛卓药业股份有限公司

CTR20241053

/ CompletedN/A

匹伐他汀钙口崩片生物等效性试验

主要研究目的研究空腹和餐后状态下单次口服受试制剂匹伐他汀钙口崩片（规格：4mg，广东万泰科创药业有限公司提供）与参比制剂匹伐他汀钙口崩片（Livalo OD，规格：4mg，持证商：興和株式会社），在健康成年受试者体内的药代动力学，评价空腹和餐后口服两种制剂的生物等效性。次要研究目的评价中国健康受试者空腹和餐后状态下，单次口服受试制剂匹伐他汀钙口崩片和参比制剂匹伐他汀钙口崩片（Livalo OD）后的安全性。

开始日期2024-05-03

申办/合作机构

广东万泰科创药业有限公司

100 项与匹伐他汀钙相关的临床结果

登录后查看更多信息

100 项与匹伐他汀钙相关的转化医学

登录后查看更多信息

100 项与匹伐他汀钙相关的专利（医药）

登录后查看更多信息

237

项与匹伐他汀钙相关的文献（医药）

2025-03-01·JAMA Cardiology

Pitavastatin, Procollagen Pathways, and Plaque Stabilization in Patients With HIV

Article

作者: Grinspoon, Steven K. ; Fichtenbaum, Carl J. ; deFilippi, Christopher ; Diggs, Marissa R. ; Foldyna, Borek ; Douglas, Pamela S. ; McCallum, Sara ; Sadreyev, Ruslan ; Lu, Michael T. ; Curran, Adrian ; Eckard, Allison Ross ; Fitch, Kathleen V. ; Currier, Judith ; Malvestutto, Carlos D. ; Karady, Julia ; Bloomfield, Gerald S. ; Aberg, Judith A. ; Mayrhofer, Thomas ; Kolossváry, Márton ; Taron, Jana ; Zanni, Markella V. ; Centinbas, Murat ; Ribaudo, Heather J. ; Schnittman, Samuel R.

Importance:

In a mechanistic substudy of the Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE) randomized clinical trial, pitavastatin reduced noncalcified plaque (NCP) volume, but specific protein and gene pathways contributing to changes in coronary plaque remain unknown.

Objective:

To use targeted discovery proteomics and transcriptomics approaches to interrogate biological pathways beyond low-density lipoprotein cholesterol (LDL-C), relating statin outcomes to reduce NCP volume and promote plaque stabilization among people with HIV (PWH).

Design, Setting, and Participants:

This was a post hoc analysis of the double-blind, placebo-controlled, REPRIEVE randomized clinical trial. Participants underwent coronary computed tomography angiography (CTA), plasma protein analysis, and transcriptomic analysis at baseline and 2-year follow-up. The trial enrolled PWH from April 2015 to February 2018 at 31 US research sites. PWH without known cardiovascular diseases taking antiretroviral therapy and with low to moderate 10-year cardiovascular risk were eligible. Data analyses were conducted from October 2023 to February 2024.

Intervention:

Oral pitavastatin calcium, 4 mg per day.

Main Outcomes and Measures:

Relative change in plasma proteomics, transcriptomics, and noncalcified plaque volume among those receiving treatment vs placebo.

Results:

Among 558 individuals (mean [SD] age, 51 [6] years; 455 male [82%]) included in the proteomics assessment, 272 (48.7%) received pitavastatin and 286 (51.3%) received placebo. After adjusting for false discovery rates, pitavastatin increased abundance of procollagen C-endopeptidase enhancer 1 (PCOLCE), neuropilin 1 (NRP-1), major histocompatibility complex class I polypeptide-related sequence A (MIC-A) and B (MIC-B), and decreased abundance of tissue factor pathway inhibitor (TFPI), tumor necrosis factor ligand superfamily member 10 (TRAIL), angiopoietin-related protein 3 (ANGPTL3), and mannose-binding protein C (MBL2). Among these proteins, the association of pitavastatin with PCOLCE (a rate-limiting enzyme of collagen deposition) was greatest, with an effect size of 24.3% (95% CI, 18.0%-30.8%; P &lt; .001). In a transcriptomic analysis, individual collagen genes and collagen gene sets showed increased expression. Among the 195 individuals with plaque at baseline (88 [45.1%] taking pitavastatin, 107 [54.9%] taking placebo), changes in NCP volume were most strongly associated with changes in PCOLCE (%change NCP volume/log2-fold change = −31.9%; 95% CI, −42.9% to −18.7%; P &lt; .001), independent of changes in LDL-C level. Increases in PCOLCE related most strongly to change in the fibro-fatty (&lt;130 Hounsfield units) component of NCP (%change fibro-fatty volume/log2-fold change = −38.5%; 95% CI, −58.1% to −9.7%; P = .01) with a directionally opposite, although nonsignificant, increase in calcified plaque (%change calcified volume/log2-fold change = 34.4%; 95% CI, −7.9% to 96.2%; P = .12).

Conclusions and Relevance:

Results of this secondary analysis of the REPRIEVE randomized clinical trial suggest that PCOLCE may be associated with the atherosclerotic plaque stabilization effects of statins by promoting collagen deposition in the extracellular matrix transforming vulnerable plaque phenotypes to more stable coronary lesions.

Trial Registration:

ClinicalTrials.gov Identifier: NCT02344290

2025-01-01·AIDS

Proteinuria and albuminuria among a global primary cardiovascular disease prevention cohort of people with HIV

Article

作者: Fichtenbaum, Carl J. ; Grinspoon, Steven K. ; Overton, Edgar T. ; Lu, Michael T. ; Douglas, Pamela S. ; McComsey, Grace A. ; Mosepele, Mosepele ; Negredo, Eugenia ; Ribaudo, Heather ; Fitch, Kathleen V. ; Malvestutto, Carlos ; Hickman, Aubri B. ; Zanni, Markella ; Wyatt, Christina ; Aberg, Judith A. ; Kantor, Amy ; Bernardino, Jose

Objective(s)::

To determine baseline prevalence of proteinuria and albuminuria among participants from the Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE) and evaluate associated risk factors.

Design::

Cross sectional analysis of a baseline sample of participants from the REPRIEVE Trial.

Methods::

REPRIEVE is an international primary cardiovascular prevention randomized controlled trial (RCT) of pitavastatin calcium vs. placebo among people with HIV (PWH) on antiretroviral therapy (ART). A representative subset (2791 participants) had urine collected at study entry. Urine protein to creatinine ratios (uPCR) and albumin to creatinine ratios (uACR) were classified as normal, moderately increased and severely increased. These were dichotomized to Normal or Abnormal for log-binomial regression analysis. Demographic, cardiometabolic, and HIV-specific data were compared among those with normal versus abnormal results.

Results::

Overall, median age 49 years, 41% female sex, 47% black or African American race, 36% had estimated glomerular filtration rate (eGFR) less than 90 ml/min/1.73 mm2. For uPCR, 27% had moderately or severely increased values. For uACR, 9% had moderately or severely increased values. In the fully adjusted model for proteinuria, female sex, older age, residence in sub-Saharan Africa or East Asia, lower BMI, lower CD4+ cell count, and use of tenofovir disoproxil fumarate (TDF) were associated with abnormal values. In the fully adjusted model for albuminuria, a diagnosis of hypertension (HTN) was associated with abnormal values.

Conclusion::

Abnormal proteinuria and albuminuria remain common (27 and 9%) despite controlled HIV. Lower current CD4+ count and TDF use were strongly associated with proteinuria. Certain modifiable comorbidities, including HTN and smoking, were associated with abnormal values. In PWH with preserved eGFR, urine measures identify subclinical kidney disease and afford the opportunity for intervention.

2024-07-01·INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES

Unveiling potential inhibitors targeting the nucleocapsid protein of SARS-CoV-2: Structural insights into their binding sites

Article

作者: Gupta, Gagan D ; Kumari, Shweta ; Bihani, Subhash C ; Mistry, Hiral ; Mukherjee, Sulakshana P

The Nucleocapsid (N) protein of SARS-CoV-2 plays a crucial role in viral replication and pathogenesis, making it an attractive target for developing antiviral therapeutics. In this study, we used differential scanning fluorimetry to establish a high-throughput screening method for identifying high-affinity ligands of N-terminal domain of the N protein (N-NTD). We screened an FDA-approved drug library of 1813 compounds and identified 102 compounds interacting with N-NTD. The screened compounds were further investigated for their ability to inhibit the nucleic-acid binding activity of the N protein using electrophoretic mobility-shift assays. We have identified three inhibitors, Ceftazidime, Sennoside A, and Tannic acid, that disrupt the N protein's interaction with RNA probe. Ceftazidime and Sennoside A exhibited nano-molar range binding affinities with N protein, determined through surface plasmon resonance. The binding sites of Ceftazidime and Sennoside A were investigated using [¹H, ¹⁵N]-heteronuclear single quantum coherence (HSQC) NMR spectroscopy. Ceftazidime and Sennoside A bind to the putative RNA binding site of the N protein, thus providing insights into the inhibitory mechanism of these compounds. These findings will contribute to the development of novel antiviral agents targeting the N protein of SARS-CoV-2.

项与匹伐他汀钙相关的新闻（医药）

2025-03-12

·GlobeNewswire-Health Care

ACTG Presents Important Findings from REPRIEVE at CROI 2025

Presentations Address Frailty, Inflammation, Asymptomatic Heart Muscle Damage, and Mental FunctionLOS ANGELES, March 12, 2025 (GLOBE NEWSWIRE) -- ACTG, a global clinical trials network focused on HIV and other infectious diseases, today presented findings from the REPRIEVE trial about the use of statins among people living with HIV with frailty and the relationship between major adverse cardiovascular events (MACE) and measurements of inflammation and asymptomatic heart muscle damage. These results were shared in two oral abstracts: “Frailty is Associated with Higher MACE Incidence but Does Not Appear to Modify Pitavastatin Effects” and “Plaque, Inflammation, Subclinical Myocardial Injury and MACE in the REPRIEVE Mechanistic Substudy” at the 2025 Conference on Retroviruses and Opportunistic Infections (CROI) in San Francisco, California. REPRIEVE (The Randomized Trial to Prevent Vascular Events in HIV) was the first large-scale clinical trial to test a primary prevention strategy to reduce the increased risk of cardiovascular disease among people living with HIV. It found that participants who took pitavastatin calcium (a daily statin pill that lowers cholesterol) reduced their risk of MACE by 36 percent compared with those receiving a placebo over a median duration of five years of follow up. “We are eager to share data from REPRIEVE at CROI about the relationship between frailty and major cardiovascular events, the importance of inflammation and asymptomatic heart muscle damage, and the impact of statin therapy on neurocognition (mental function) and heart failure risk,” said ACTG Chair Joseph J. Eron, M.D., University of North Carolina. “REPRIEVE was a groundbreaking study that has informed a multitude of international guidelines, which now recommend statins to prevent cardiovascular disease in many people living with HIV and we expect that it will continue to generate meaningful findings that improve the care of people living with HIV.” Frailty is Associated with Higher MACE Incidence but Does Not Appear to Modify Pitavastatin EffectsToday’s presentation examined whether frailty is associated with MACE among people living with HIV and whether statins may prevent MACE across a spectrum of frailty. Researchers found that higher levels of frailty were associated with increased risk of MACE among participants. They also determined that while adults living with HIV and frailty were routinely under-prescribed key preventive therapies such as statins, frailty status did not appear to modify the protective effects of pitavastatin that were seen in the primary trial. While further research is needed, the study concluded that incorporating frailty assessments such as the frailty index may help identify people living with HIV who are at risk of MACE. “The strong association in this analysis between the age-related syndrome of frailty and major adverse cardiovascular events may suggest similar underlying mechanisms and, further, that screening for frailty can help identify the participants at highest risk for cardiovascular events,” said Presenting Author Kristine Erlandson, M.D., University of Colorado Anschutz Medical Campus. “While providers and patients may question the added benefit of statins in patients with numerous comorbidities, the data presented today support the use of pitavastatin among adults living with HIV and frailty.” Plaque, Inflammation, Subclinical Myocardial Injury and MACE in the REPRIEVE Mechanistic SubstudyThis secondary analysis presented today assessed for the first time the relationship between coronary plaque and measurements of inflammation and asymptomatic heart muscle damage with MACE. Today’s presentation demonstrated that among participants in REPRIEVE’s mechanistic substudy, individuals with noncalcified coronary plaque (buildup of plaque in the arteries that can cause a heart attack) and higher blood levels of inflammation and heart muscle injury at study entry were at higher risk of having a cardiovascular event over six years of follow up even though they did not have symptoms. In exploratory analyses, plaque and biomarker (blood proteins associated with cardiovascular disease) combinations further improved the accuracy of predicting the risk of MACE beyond traditional risk scores. The data also suggested that the benefit of pitavastatin to prevent MACE may be greater among individuals who have noncalcified coronary plaque and evidence of low-grade myocardial damage, which may precede symptoms. Additional investigation is necessary to determine how pitavastatin can be most effective for these individuals. “These data suggest that key plaque, inflammatory, and asymptomatic heart muscle damage markers are strongly related to MACE, even among people living with HIV who are not experiencing cardiac-related symptoms,” said Presenting Author and Study Chair Steven Grinspoon, M.D, Harvard Medical School and Massachusetts General Hospital. “These data highlight the need for additional studies to identify people living with HIV who might benefit most from statin therapy and to identify new mechanistic pathways to target,” said REPRIEVE Mechanistic Substudy Protocol Chair and Lead Author Michael Lu, M.D., M.P.H., Harvard Medical School and Massachusetts General Hospital. ACTG also presented two posters at CROI reporting on additional REPRIEVE findings: No Evidence of a Detrimental Effect of Pitavastatin on Neurocognitive Function Among People with HIV found no evidence to suggest that pitavastatin impacted neurocognitive function among people living with HIV at low to moderate cardiovascular disease risk, even among those who entered the study with some existing level of impairment.“Concerns about potential detrimental cognitive effects of statins are often raised when considering statin therapy,” said Presenting Author Dr. Erlandson. “The results from this randomized, blinded study, which show no relationship between statin therapy and change in neurocognitive function, should provide reassurance to patients and providers.” Heart Failure Risk and Events In People with HIV: The Randomized Trial To Prevent Vascular Events In HIV (REPRIEVE)” (Gerald Bloomfield, et al.) found that the number of heart failure events among people living with HIV in REPRIEVE was consistent with the low estimated PREVENT (Predicting Risk of Cardiovascular Disease Events) heart failure risk rates. Participants who were Black, female, lived in sub-Saharan Africa, had pre-existing hypertension, and/or elevated body mass were more likely to experience heart failure. REPRIEVE began in 2015 as cooperative agreements (HL12339, HL123336, HL164284, and HL164285) and was a collaborative effort between the National Institutes of Health’s National Heart, Lung, and Blood Institute (NHLBI) and the National Institute of Allergy and Infectious Diseases (NIAID), two of the largest NIH institutes, and ACTG (AI068636). It received additional funding from the NIH Office of AIDS Research, Kowa Pharmaceuticals America, Inc. (providers of pitavastatin calcium and placebo), Gilead Sciences, Inc., and ViiV HealthCare. The study is led by Dr. Grinspoon and Pamela S. Douglas, M.D., Duke University School of Medicine (Co-chair), who led the Clinical Coordinating Center and Heather Ribaudo, Ph.D., Harvard School of Public Health (Lead Statistician) and Dr. Lu, who led the Data Coordinating Center. ACTG is led by Dr. Eron and Rajesh T. Gandhi, M.D., Massachusetts General Hospital and Harvard Medical School (ACTG Vice-Chair). To learn more, please visit www.reprievetrial.org. About ACTG ACTG is the world’s largest and longest running clinical trials network focused on HIV and other infectious diseases and the people living with them. It is funded by NIAID and collaborating NIH Institutes. Founded in 1987, ACTG conducts research to improve the management of HIV and its comorbidities; develop a cure for HIV; and innovate treatments for tuberculosis, hepatitis B, and emerging infectious diseases. It comprises thousands of dedicated researchers, staff, and community members who are pursuing research into novel treatments and cures for infectious diseases at 65 locations across four continents, with the ultimate goal of advancing science that meaningfully impacts the lives of the people we serve. Disclaimer: This content is solely the responsibility of ACTG and does not necessarily represent the official views of the NIH. Media Contact:Rachel Reiss, ACTGRLReiss@mednet.ucla.edu

临床研究临床结果

2025-03-04

·米内网

科伦、齐鲁……冲刺口服降脂药首仿！TOP20洗牌，20亿大品种领跑，海正、京新、方盛上榜

精彩内容近期，内服血脂调节剂市场新品不断，北京四环科宝制药的氟伐他汀钠缓释片以仿制4类报产在审。今年以来，内服血脂调节剂已有11个品种（28个受理号）报产在审，科伦药业、齐鲁制药等冲刺首仿。米内网数据显示，内服血脂调节剂（化+生）在2024年Q1-Q3在中国零售药店终端同比增长超过12%，TOP20中，20亿大品种领跑，独家产品暴涨112%，海正药业、京新药业、神奇制药、方盛制药等上榜。大涨12%，晖致、阿斯利康、欧加农位居前三近年中国零售药店终端内服血脂调节剂销售情况（单位：亿元）来源：米内网格局数据库米内网数据显示，内服血脂调节剂（化+生）在近年中国零售药店（城市实体药店和网上药店）终端市场规模稳步增长，均超过50亿元，2024年Q1-Q3同比增长12.37%。其中，城市实体药店是主要销售渠道；网上药店则快速增长，销售额已超过2023年全年。 2024年Q1-Q3中国零售药店终端内服血脂调节剂集团TOP5来源：米内网格局数据库从集团TOP20来看，晖致、阿斯利康、欧加农制药、浙江海正药业、乐普医疗位居前五，方盛制药增速（162.59%）最快，首次晋身TOP20。从治疗小类来看，HMGCoA还原酶抑制剂市场份额最大，占超过8成，其他血脂调节剂则增速最快。从在销品种数量来看，产品超过60个，品牌超过280个。 20亿大品种领跑，独家产品暴涨112%，京新、方盛上榜 2024年Q1-Q3中国零售药店终端内服血脂调节剂产品TOP20（单位：亿元）来源：米内网格局数据库注：销售额不足1亿元以*表示，标红为独家产品产品TOP20中，阿托伐他汀钙片多年来稳居“销冠”宝座，以超20亿元的销售规模领跑，瑞舒伐他汀钙片则紧跟其后。从增速来看，维E三油胶丸（112.05%）是唯一一个翻倍的产品，瑞舒伐他汀钙片（25.49%）、依折麦布片（34.36%）、非诺贝特胶囊（18.10%）、多烯酸乙酯软胶囊（26.75%）、海博麦布片（74.39%）、ω-3脂肪酸乙酯90软胶囊（94.27%）、匹伐他汀钙分散片（29.00%）均有双位数增速。 6个独家品种中，阿托伐他汀钙分散片（广东九瑞科技）、海博麦布片（浙江海正药业）、维E三油胶丸（贵州神奇药业）、匹伐他汀钙分散片（京新药业）在近年均持续增长。 2024年Q1-Q3中国零售药店终端内服血脂调节剂品牌TOP20（单位：亿元）来源：米内网格局数据库注：销售额不足1亿元以*表示品牌TOP20中，晖致的阿托伐他汀钙片和阿斯利康的瑞舒伐他汀钙片销售额均超过10亿元。北京福元医药的阿托伐他汀钙片、浙江海正药业的海博麦布片等5个品牌新上榜，其中，斯洛文尼亚莱柯的瑞舒伐他汀钙片（302.57%）、湖南方盛制药的依折麦布片（162.59%）、贵州神奇药业的维E三油胶丸（112.05%）均增速翻倍。依折麦布片在近年中国零售药店终端保持双位数增速，2024年Q1-Q3销售额已超过3亿元，接近2023年全年。欧加农制药的市场份额最大；湖南方盛制药位居第二，市场份额从2021年不足1%到2024年Q1-Q3超过8%。海博麦布片是浙江海正药业的1类新药，该产品在近年中国零售药店终端市场规模快速扩容，2023年-2024年Q1-Q3分别同比增长289.19%、74.39%，跃升到内服血脂调节剂（化+生）TOP11产品。海正药业表示，海博麦布片被纳入《中国血脂管理指南（基层版2024年）》《糖尿病患者血脂管理中国专家共识（2024版）》《中国慢性冠脉综合征患者诊断及管理指南》，提升其在胆固醇领域的治疗地位，公司将持续加速产品的市场覆盖和准入进程。科伦、齐鲁……猛攻首仿，海正改良型新药来袭今年以来报产在审的内服血脂调节剂来源：米内网中国申报进度（MED）数据库近日，CDE官网显示，北京四环科宝制药的氟伐他汀钠缓释片以仿制4类报产在审。在此之前，齐鲁制药（海南）的瑞舒伐他汀依折麦布片(Ⅰ)、四川科伦药业的瑞舒伐他汀依折麦布片(Ⅰ)等3个产品同日报产。今年以来，内服血脂调节剂已有11个品种（28个受理号）报产在审，瑞舒伐他汀依折麦布片(Ⅰ)和瑞舒伐他汀依折麦布片(Ⅱ)暂无仿制药获批，而瑞舒伐他汀依折麦布片(Ⅰ)竞争最激烈，目前共有20家企业报产在审，其中，齐鲁制药（海南）、四川科伦药业、江西施美药业、山东齐都药业等9家企业均在今年报产。来源：米内网项目进度数据库此外，海博麦布阿托伐他汀钙片为瀚晖制药|浙江海正药业的2.3类改良型新药。资料显示，该产品作为饮食控制以外的辅助治疗，拟用于治疗原发性（杂合子家族性或非家族性）高胆固醇血症或混合性高脂血症，可降低总胆固醇（TC）、低密度脂蛋白胆固醇（LDL-C）、载脂蛋白B（ApoB）水平和甘油三酯(TG)水平。资料来源：米内网数据库、公司公告等注：米内网《中国城市实体药店药品终端竞争格局》，统计范围是：全国地级及以上城市实体药店，不含县乡村药店；《中国网上药店药品终端竞争格局》，统计范围是：全国网上药店所有药品数据，包括天猫、京东等第三方平台及私域平台上所有网上药店药品数据；上述销售额以产品在终端的平均零售价计算。如有疏漏，欢迎指正！免责声明：本文仅作医药信息传播分享，并不构成投资或决策建议。本文为原创稿件，转载文章或引用数据请注明来源和作者，否则将追究侵权责任。投稿及报料请发邮件到872470254@qq.com稿件要求详询米内微信首页菜单栏商务及内容合作可联系QQ：412539092 【分享、点赞、在看】点一点不失联哦

申请上市IPO

2025-02-20

·国家药品监督管理局

国家药监局公布药品说明书适老化及无障碍改革试点名单（第四批）

根据《国家药监局关于发布药品说明书适老化及无障碍改革试点工作方案的公告》（2023年第142号），省级药品监管部门和国家药监局药品审评中心报送了参与试点的药品上市许可持有人和药品名单（第四批），现予公布。序号药品名称药品上市许可持有人1替格瑞洛片华润双鹤药业股份有限公司2非布司他片华润双鹤药业股份有限公司3盐酸贝那普利片北京诺华制药有限公司4甲钴胺片辽宁亿帆药业有限公司5布洛伪麻片辽宁亿帆药业有限公司6盐酸奈福泮片辽宁亿帆药业有限公司7红霉素肠溶片辽宁亿帆药业有限公司8乙酰螺旋霉素片辽宁亿帆药业有限公司9双氯芬酸钠肠溶片辽宁亿帆药业有限公司10益肝灵片辽宁亿帆药业有限公司11复方磺胺甲噁唑片辽宁亿帆药业有限公司12盐酸莫雷西嗪片辽宁亿帆药业有限公司13复方茶碱甲麻黄碱片辽宁亿帆药业有限公司14复方妥英麻黄茶碱片辽宁亿帆药业有限公司15伤科跌打片辽宁亿帆药业有限公司16清脑降压片辽宁亿帆药业有限公司17格列本脲片辽宁亿帆药业有限公司18复方阿司匹林片辽宁亿帆药业有限公司19磷酸苯丙哌林胶囊辽宁亿帆药业有限公司20盐酸环丙沙星胶嚢辽宁亿帆药业有限公司21通便灵胶囊辽宁亿帆药业有限公司22氨咖黄敏胶囊朝阳龙城制药有限公司23对乙酰氨基酚片朝阳龙城制药有限公司24复方龙胆碳酸氢钠片朝阳龙城制药有限公司25维D2磷酸氢钙片朝阳龙城制药有限公司26独一味颗粒朝阳龙城制药有限公司27酒石酸美托洛尔片翎耀生物科技（上海）有限公司28利培酮口服溶液翎耀生物科技（上海）有限公司29阿托伐他汀钙片翎耀生物科技（上海）有限公司30利伐沙班片翎耀生物科技（上海）有限公司31氨己烯酸口服溶液用散翎耀生物科技（上海）有限公司32美洛昔康片上海勃林格殷格翰药业有限公司33利奈唑胺片上海迪赛诺医药集团股份有限公司34富马酸丙酚替诺福韦片上海迪赛诺医药集团股份有限公司35齐多拉米双夫定片上海迪赛诺医药集团股份有限公司36扶正化瘀胶囊上海黄海制药有限责任公司37扶正化瘀片上海黄海制药有限责任公司38替米沙坦片上海现代制药股份有限公司39硝苯地平片上海信谊天平药业有限公司40盐酸氨溴索胶囊上海信谊天平药业有限公司41卡托普利片上海信谊天平药业有限公司42辛伐他汀片上海信谊万象药业股份有限公司43甲氨蝶呤片上海上药信谊药厂有限公司44盐酸二甲双胍片上海上药信谊药厂有限公司45雷贝拉唑钠肠溶片上海上药信谊药厂有限公司46瑞舒伐他汀钙片上海上药信谊药厂有限公司47卡培他滨片上海上药信谊药厂有限公司48双氯芬酸钠缓释片上海上药信谊药厂有限公司49盐酸二甲双胍缓释片上海上药信谊药厂有限公司50盐酸胺碘酮片上海上药信谊药厂有限公司51酚氨咖敏片上海上药信谊药厂有限公司52复方甲氧那明胶囊上海上药信谊药厂有限公司53洛索洛芬钠片上海旭东海普药业有限公司54复方卡托普利片上海旭东海普药业有限公司55盐酸氟桂利嗪胶囊上海旭东海普药业有限公司56盐酸安非他酮缓释片（Ⅱ）上海宣泰医药科技股份有限公司57盐酸帕罗西汀肠溶缓释片上海宣泰医药科技股份有限公司58头孢丙烯胶囊上海新亚药业闵行有限公司59头孢拉定胶囊上海新亚药业闵行有限公司60盐酸克林霉素胶囊上海新亚药业闵行有限公司61阿莫西林克拉维酸钾分散片上海新亚药业闵行有限公司62复方磺胺甲噁唑片上海新亚药业闵行有限公司63头孢克肟分散片上海新亚药业闵行有限公司64甲钴胺片上海新亚药业闵行有限公司65单硝酸异山梨酯缓释片上海新亚药业闵行有限公司66丙酸氯倍他索乳膏上海新亚药业闵行有限公司67林可霉素利多卡因凝胶上海新亚药业闵行有限公司68六神丸上海雷允上药业有限公司69关节镇痛巴布膏上海雷允上药业有限公司70通塞脉胶囊江苏康缘阳光药业有限公司71淫羊藿总黄酮胶囊江苏康缘阳光药业有限公司72夜宁胶囊江苏康缘阳光药业有限公司73通塞脉片江苏康缘阳光药业有限公司74参乌益肾片江苏康缘阳光药业有限公司75六味地黄软胶囊江苏康缘阳光药业有限公司76银翘解毒软胶囊江苏康缘阳光药业有限公司77元胡止痛软胶囊江苏康缘阳光药业有限公司78七味通痹口服液江苏康缘阳光药业有限公司79小儿氨酚黄那敏颗粒江苏康缘阳光药业有限公司80非那雄胺片南京海鲸药业股份有限公司81维生素D2软胶囊南京海鲸药业股份有限公司82瑞舒伐他汀钙片南京正大天晴制药有限公司83替格瑞洛片南京正大天晴制药有限公司84枸橼酸托法替布片南京正大天晴制药有限公司85利伐沙班片南京正大天晴制药有限公司86氟唑帕利胶囊江苏恒瑞医药股份有限公司87脯氨酸恒格列净片江苏恒瑞医药股份有限公司88爱普列特片江苏联环药业股份有限公司89苯磺酸左氨氯地平片苏州东瑞制药有限公司90甲磺酸氟马替尼片江苏豪森药业集团有限公司91替米沙坦氢氯噻嗪片常州制药厂有限公司92达格列净片昆山龙灯瑞迪制药有限公司93马来酸氟伏沙明片昆山龙灯瑞迪制药有限公司94二甲双胍恩格列净片（Ⅰ）杭州中美华东制药有限公司95吡格列酮二甲双胍片杭州中美华东制药有限公司96环孢素软胶囊杭州中美华东制药有限公司97克拉霉素片杭州中美华东制药有限公司98他克莫司胶囊杭州中美华东制药有限公司99吗替麦考酚酯分散片杭州中美华东制药有限公司100吗替麦考酚酯片杭州中美华东制药有限公司101吗替麦考酚酯胶囊杭州中美华东制药有限公司102盐酸吡格列酮片杭州中美华东制药有限公司103阿那曲唑片杭州中美华东制药有限公司104吲哚布芬片杭州中美华东制药有限公司105左氧氟沙星片浙江普洛康裕制药有限公司106非布司他片杭州朱养心药业有限公司107利伐沙班片杭州朱养心药业有限公司108硫酸氨基葡萄糖胶囊浙江施强制药有限公司109盐酸伐地那非片浙江施强制药有限公司110替格瑞洛片浙江海正药业股份有限公司111吗替麦考酚酯片浙江海正药业股份有限公司112瑞舒伐他汀钙片瀚晖制药有限公司113左氧氟沙星滴眼液浙江莎普爱思药业股份有限公司114头孢克肟分散片浙江莎普爱思药业股份有限公司115左氧氟沙星片浙江京新药业股份有限公司116瑞舒伐他汀钙片浙江京新药业股份有限公司117苯磺酸氨氯地平片浙江京新药业股份有限公司118阿司匹林肠溶片浙江京新药业股份有限公司119匹伐他汀钙分散片浙江京新药业股份有限公司120阿托伐他汀钙片浙江京新药业股份有限公司121左乙拉西坦片浙江京新药业股份有限公司122盐酸普拉克索片浙江京新药业股份有限公司123盐酸舍曲林片浙江京新药业股份有限公司124复方鱼腥草合剂浙江康恩贝中药有限公司125普瑞巴林胶囊浙江昂利康制药股份有限公司126碳酸镧咀嚼片浙江昂利康制药股份有限公司127利丙双卡因乳膏浙江昂利康制药股份有限公司128磷酸奥司他韦胶囊浙江华海药业股份有限公司129艾司奥美拉唑镁肠溶胶囊浙江华海药业股份有限公司130盐酸度洛西汀肠溶胶囊浙江华海药业股份有限公司131左乙拉西坦缓释片浙江华海药业股份有限公司132培哚普利叔丁胺片浙江华海药业股份有限公司133阿哌沙班片浙江华海药业股份有限公司134非布司他片浙江华海药业股份有限公司135利培酮分散片浙江华海药业股份有限公司136复方鲜竹沥液江西药都樟树制药有限公司137跌打损伤丸江西药都樟树制药有限公司138强力枇杷露江西药都樟树制药有限公司139荷丹片江西沃华济顺医药有限公司140荷丹胶囊江西沃华济顺医药有限公司141硝苯地平控释片江西山香药业有限公司142米拉贝隆缓释片江西山香药业有限公司143奥拉帕利片江西山香药业有限公司144罗沙司他胶囊江西山香药业有限公司145肠炎宁片江西康恩贝中药有限公司146牛黄上清胶囊江西康恩贝中药有限公司147清肝利胆胶囊江西康恩贝中药有限公司148盐酸达泊西汀片江西制药有限责任公司149米诺地尔搽剂山东京卫制药有限公司150乳果糖口服溶液山东京卫制药有限公司151利多卡因氯己定气雾剂山东京卫制药有限公司152丙酸倍氯米松鼻气雾剂山东京卫制药有限公司153水杨酸甲酯气雾剂山东京卫制药有限公司154富马酸酮替芬鼻喷雾剂山东京卫制药有限公司155盐酸索他洛尔片鲁南贝特制药有限公司156阿昔莫司胶囊鲁南贝特制药有限公司157单硝酸异山梨酯分散片鲁南贝特制药有限公司158单硝酸异山梨酯缓释片鲁南贝特制药有限公司159瑞舒伐他汀钙胶囊鲁南贝特制药有限公司160奥美拉唑碳酸氢钠胶囊鲁南贝特制药有限公司161奥美拉唑碳酸氢钠胶囊（Ⅱ）鲁南贝特制药有限公司162非诺贝特酸胆碱缓释胶囊鲁南贝特制药有限公司163恩格列净片山东新时代药业有限公司164枸橼酸托法替布片山东鲁抗医药股份有限公司165盐酸莫西沙星片山东鲁抗医药股份有限公司166替格瑞洛片山东鲁抗医药股份有限公司167头孢氨苄片山东鲁抗医药股份有限公司168阿莫西林胶囊山东鲁抗医药股份有限公司169头孢氨苄胶囊山东鲁抗医药股份有限公司170他达拉非片山东明仁福瑞达制药股份有限公司171盐酸二甲双胍缓释片山东明仁福瑞达制药股份有限公司172氯化钾缓释片宜昌人福药业有限责任公司173磷酸奥司他韦胶囊宜昌人福药业有限责任公司174麦考酚钠肠溶片宜昌人福药业有限责任公司175阿奇霉素干混悬剂宜昌人福药业有限责任公司176阿奇霉素胶囊宜昌人福药业有限责任公司177恩替卡韦片宜昌人福药业有限责任公司178利伐沙班片宜昌人福药业有限责任公司179维生素C片宜昌人福药业有限责任公司180维生素B1片宜昌人福药业有限责任公司181烟酸缓释片宜昌人福药业有限责任公司182塞来昔布胶囊宜昌人福药业有限责任公司183非那雄胺片武汉人福药业有限责任公司184福多司坦片宜昌东阳光长江药业股份有限公司185苯磺酸氨氯地平片宜昌东阳光长江药业股份有限公司186阿奇霉素胶囊宜昌东阳光长江药业股份有限公司187阿奇霉素干混悬剂宜昌东阳光长江药业股份有限公司188磷酸奥司他韦胶囊宜昌东阳光长江药业股份有限公司189磷酸依米他韦胶囊宜昌东阳光长江药业股份有限公司190索磷布韦片宜昌东阳光长江药业股份有限公司191碳酸氢钠片远大医药（中国）有限公司192盐酸曲美他嗪片远大医药（中国）有限公司193替米沙坦氢氯噻嗪片远大医药（中国）有限公司194硫酸羟氯喹片远大医药（中国）有限公司195格列吡嗪片远大医药（中国）有限公司196玻璃酸钠滴眼液湖北远大天天明制药有限公司197妥布霉素滴眼液湖北远大天天明制药有限公司198复方甘草片湖南尔康制药股份有限公司199盐酸特比萘芬喷雾剂湖南及正医药科技有限公司200硝苯地平缓释片（Ⅰ）国药集团广东环球制药有限公司201硝苯地平缓释片（Ⅲ）国药集团广东环球制药有限公司202感冒灵颗粒华润三九医药股份有限公司203硫酸氢氯吡格雷片东莞市阳之康医药有限责任公司204阿奇霉素片东莞市阳之康医药有限责任公司205琥珀酸美托洛尔缓释片东莞市阳之康医药有限责任公司206枸橼酸西地那非片东莞市阳之康医药有限责任公司207阿托伐他汀钙片东莞市阳之康医药有限责任公司208利伐沙班片东莞市阳之康医药有限责任公司209恩他卡朋片东莞市阳之康医药有限责任公司210左氧氟沙星片东莞市阳之康医药有限责任公司211克拉霉素片东莞市阳之康医药有限责任公司212克拉霉素缓释片东莞市阳之康医药有限责任公司213磷酸奥司他韦干混悬剂广东东阳光药业股份有限公司214磷酸奥司他韦胶囊广东东阳光药业股份有限公司215盐酸二甲双胍片广东东阳光药业股份有限公司216瑞舒伐他汀钙片广东东阳光药业股份有限公司217他达拉非片广东东阳光药业股份有限公司218奥氮平片广东东阳光药业股份有限公司219利格列汀二甲双胍片（Ⅰ）广东东阳光药业股份有限公司220利格列汀二甲双胍片（Ⅱ）广东东阳光药业股份有限公司221利格列汀二甲双胍片（Ⅲ）广东东阳光药业股份有限公司222恩替卡韦片广东东阳光药业股份有限公司223利托那韦片广东东阳光药业股份有限公司224氢溴酸加兰他敏口腔崩解片广东东阳光药业股份有限公司225脑心清片广州白云山和记黄埔中药有限公司226绞股蓝总甙片广州白云山和记黄埔中药有限公司227消炎利胆片广州白云山和记黄埔中药有限公司228护肝片广州白云山和记黄埔中药有限公司229痰咳净散广州王老吉药业股份有限公司230痰咳净片广州王老吉药业股份有限公司231跌打榜药酒广东恒诚制药股份有限公司232风油精广东恒诚制药股份有限公司233复方醋酸曲安奈德溶液广东恒诚制药股份有限公司234复方苦参水杨酸散广东恒诚制药股份有限公司235复方鱼腥草片广东恒诚制药股份有限公司236腹可安片广东恒诚制药股份有限公司237感冒伤风咳茶广东恒诚制药股份有限公司238结石通片广东恒诚制药股份有限公司239橘红枇杷片广东恒诚制药股份有限公司240七星茶广东恒诚制药股份有限公司241清热除湿止泻合剂广东恒诚制药股份有限公司242清热除湿止泻颗粒广东恒诚制药股份有限公司243锁仙补肾口服液广东恒诚制药股份有限公司244板蓝根颗粒广东恒诚制药股份有限公司245风寒感冒颗粒广东恒诚制药股份有限公司246风热感冒颗粒广东恒诚制药股份有限公司247复方春砂颗粒广东恒诚制药股份有限公司248感冒清热颗粒广东恒诚制药股份有限公司249感冒止咳颗粒广东恒诚制药股份有限公司250金菊五花茶颗粒广东恒诚制药股份有限公司251小儿七星茶颗粒广东恒诚制药股份有限公司252野菊花颗粒广东恒诚制药股份有限公司253银翘解毒颗粒广东恒诚制药股份有限公司254止咳枇杷颗粒广东恒诚制药股份有限公司255山楂麦曲颗粒广东恒诚制药股份有限公司256生脉颗粒(党参方)广东恒诚制药股份有限公司257寒喘丸广东恒诚制药股份有限公司258藿胆丸广东恒诚制药股份有限公司259大黄䗪虫丸广东恒诚制药股份有限公司260强力枇杷露广东恒诚制药股份有限公司261首乌补肾酒广东恒诚制药股份有限公司262维C银翘片广东恒诚制药股份有限公司263香砂六君丸广东恒诚制药股份有限公司264香砂养胃丸广东恒诚制药股份有限公司265壮腰健肾丸广东恒诚制药股份有限公司266感冒清片广东恒诚制药股份有限公司267巴戟补酒广东恒诚制药股份有限公司268川贝枇杷糖浆广东恒诚制药股份有限公司269胆香鼻炎片广东恒诚制药股份有限公司270复方海蛇酊广东恒诚制药股份有限公司271咳特灵胶囊广东恒诚制药股份有限公司272止咳枇杷糖浆广东恒诚制药股份有限公司273健儿素颗粒广东恒诚制药股份有限公司274健脾颗粒广东恒诚制药股份有限公司275复方南板蓝根颗粒广东恒诚制药股份有限公司276壮腰健肾丸广州白云山陈李济药厂有限公司277昆仙胶囊广州白云山陈李济药厂有限公司278咳喘顺丸广州白云山陈李济药厂有限公司279上清丸广州白云山陈李济药厂有限公司280乌鸡白凤丸广州白云山陈李济药厂有限公司281补脾益肠丸广州白云山陈李济药厂有限公司282舒筋健腰丸广州白云山陈李济药厂有限公司283胃疡宁丸广州白云山陈李济药厂有限公司284妇科养坤丸广州白云山陈李济药厂有限公司285新血宝胶囊广州白云山陈李济药厂有限公司286喉疾灵胶囊广州白云山陈李济药厂有限公司287雷贝拉唑钠肠溶胶囊珠海润都制药股份有限公司288盐酸伐昔洛韦片珠海润都制药股份有限公司289单硝酸异山梨酯缓释胶囊珠海润都制药股份有限公司290双氯芬酸钠缓释胶囊珠海润都制药股份有限公司291雷贝拉唑钠肠溶片珠海润都制药股份有限公司292奥美沙坦酯片珠海润都制药股份有限公司293缬沙坦片珠海润都制药股份有限公司294奥美沙坦酯氢氯噻嗪片珠海润都制药股份有限公司295盐酸伊托必利胶囊珠海润都制药股份有限公司296奥美拉唑肠溶胶囊珠海润都制药股份有限公司297厄贝沙坦胶囊珠海润都制药股份有限公司298吲达帕胺胶囊珠海润都制药股份有限公司299盐酸二甲双胍肠溶胶囊珠海润都制药股份有限公司300阿奇霉素肠溶胶囊珠海润都制药股份有限公司301布洛芬缓释胶囊珠海润都制药股份有限公司302盐酸伊托必利片珠海润都制药股份有限公司303厄贝沙坦片珠海润都制药股份有限公司304缬沙坦氢氯噻嗪片珠海润都制药股份有限公司305茶碱缓释片珠海润都制药股份有限公司306利培酮口服溶液万特制药（海南）有限公司307泊沙康唑肠溶片四川科伦药业股份有限公司308盐酸奥洛他定片四川子仁制药有限公司309磷酸奥司他韦干混悬剂四川子仁制药有限公司310复方酮康唑发用洗剂滇虹药业集团股份有限公司311消食健脾丸红云制药（玉溪）有限公司312七味糖脉舒胶囊昆明龙津药业股份有限公司313生脉饮云南白药集团股份有限公司314银黄口服液云南白药集团股份有限公司315舒列安胶囊云南白药集团股份有限公司316阿奇霉素胶囊云南白药集团股份有限公司317紫楼胃康胶囊云南白药集团股份有限公司318复方牛黄消炎胶囊云南白药集团股份有限公司319诺氟沙星胶囊云南白药集团股份有限公司320田七痛经胶囊云南白药集团股份有限公司321炎可宁胶囊云南白药集团股份有限公司322香砂平胃颗粒云南白药集团股份有限公司323新生化颗粒云南白药集团股份有限公司324田七花叶颗粒云南白药集团股份有限公司325小柴胡颗粒云南白药集团股份有限公司326千紫红颗粒云南白药集团股份有限公司327酚氨咖敏颗粒云南白药集团股份有限公司328小儿解表颗粒云南白药集团股份有限公司329小儿清咽颗粒云南白药集团股份有限公司330小儿感冒颗粒云南白药集团股份有限公司331感冒止咳颗粒云南白药集团股份有限公司332阿司匹林肠溶片云南白药集团股份有限公司333土霉素片云南白药集团股份有限公司334复方南板蓝根片云南白药集团股份有限公司335香砂养胃片云南白药集团股份有限公司336复方岩白菜素片云南白药集团股份有限公司337健胃消食片云南白药集团股份有限公司338克林霉素磷酸酯片云南白药集团股份有限公司339利胆止痛片云南白药集团股份有限公司340消渴灵片云南白药集团股份有限公司341养肝明目片云南白药集团股份有限公司342银杏叶片云南白药集团股份有限公司343云南花粉片云南白药集团股份有限公司344葡萄糖粉剂云南白药集团股份有限公司345生三七散云南白药集团股份有限公司346肿痛凝胶云南白药集团股份有限公司347肿痛搽剂云南白药集团股份有限公司348益脉康片云南白药集团大理药业有限责任公司349益脉康分散片云南白药集团大理药业有限责任公司350清肺抑火片云南白药集团大理药业有限责任公司351通宣理肺片云南白药集团大理药业有限责任公司352泻痢消片云南白药集团大理药业有限责任公司353开胸消食片云南白药集团大理药业有限责任公司354小儿导赤片云南白药集团大理药业有限责任公司355复方黄连素片云南白药集团大理药业有限责任公司356三黄片云南白药集团大理药业有限责任公司357牛黄解毒片云南白药集团大理药业有限责任公司358竹红菌素软膏云南白药集团大理药业有限责任公司359宁心宝胶囊云南白药集团大理药业有限责任公司360六味地黄丸云南白药集团大理药业有限责任公司361妇舒丸云南白药集团大理药业有限责任公司362乳酸菌素片云南白药集团大理药业有限责任公司363氨咖黄敏片云南白药集团大理药业有限责任公司364豆腐果苷片云南白药集团大理药业有限责任公司365硫酸亚铁片云南白药集团大理药业有限责任公司366盐酸小檗碱胶囊云南白药集团大理药业有限责任公司367阿咖酚散云南白药集团大理药业有限责任公司368陈香露白露片云南白药集团大理药业有限责任公司369灯盏花素片云南白药集团大理药业有限责任公司370千金藤素片云南白药集团大理药业有限责任公司371盐酸小檗碱片云南白药集团大理药业有限责任公司372维生素C片云南白药集团大理药业有限责任公司373元胡止痛片云南白药集团大理药业有限责任公司374知柏地黄丸云南白药集团大理药业有限责任公司375气血康胶囊云南白药集团文山七花有限责任公司376气血康片云南白药集团文山七花有限责任公司377盐酸氟桂利嗪胶囊西安杨森制药有限公司378和血明目片西安碑林药业股份有限公司379金嗓开音丸西安碑林药业股份有限公司380金嗓利咽丸西安碑林药业股份有限公司381金嗓散结丸西安碑林药业股份有限公司382金嗓开音胶囊西安碑林药业股份有限公司383金嗓利咽胶囊西安碑林药业股份有限公司384金嗓散结胶囊西安碑林药业股份有限公司385金嗓开音片西安碑林药业股份有限公司386金嗓散结颗粒西安碑林药业股份有限公司387金嗓开音颗粒西安碑林药业股份有限公司388甲磺酸普雷福韦片西安葛蓝新通制药有限公司389西黄丸陕西季诺康禾药业有限公司390盐酸多奈哌齐片药云（西安）医药技术有限公司391盐酸托莫西汀口服溶液西安远大科创医药科技有限公司392固肠止泻丸陕西中医药大学制药厂393天麻眩晕宁合剂陕西中医药大学制药厂394消炎退热合剂陕西中医药大学制药厂395四季抗病毒合剂陕西海天制药有限公司396阿娜尔妇洁液陕西海天制药有限公司397枣仁安神颗粒西安万隆制药股份有限公司398固精麦斯哈片西安万隆制药股份有限公司399乌龙散西安万隆制药股份有限公司400保和丸陕西紫光辰济药业有限公司401大山楂丸陕西紫光辰济药业有限公司402济生肾气丸陕西紫光辰济药业有限公司403消积丸陕西紫光辰济药业有限公司404致康胶囊西安千禾药业股份有限公司405痫愈胶囊西安千禾药业股份有限公司406缬沙坦氢氯噻嗪片Novartis Pharma Schweiz AG407奥卡西平片Novartis Pharma Schweiz AG408依伏卡塞片Kyowa Kirin Co., Ltd.409阿帕他胺片Janssen-Cilag International NV410沙格列汀片AstraZeneca AB411沙格列汀二甲双胍缓释片（Ⅰ）AstraZeneca AB412沙格列汀二甲双胍缓释片（Ⅱ）AstraZeneca AB413沙格列汀二甲双胍缓释片（Ⅲ）AstraZeneca AB414拉西地平片GLAXOSMITHKLINE, S.A.415吲哚美辛巴布膏Nipro Pharma Corporation

医药出海

100 项与匹伐他汀钙相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D01862	匹伐他汀钙	C10AA08	DB08860

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
家族性混合型高脂血症	美国	Kowa Co., Ltd.	2019-05-16
杂合子家族性高胆固醇血症	澳大利亚	Advantage Medical Products LLC	2013-08-27
血脂障碍	中国	Kowa Co., Ltd.	2008-09-28
高脂血症	印度	Zydus Lifesciences Ltd.	2005-02-21
高胆固醇血症	日本	Kowa Co., Ltd.	2003-07-17
II型高脂蛋白血症	日本	Kowa Co., Ltd.	2003-07-17

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
原发性高脂血症	临床3期	美国	Kowa Research Institute, Inc.	2016-01-01
HIV感染	临床1期	美国	Kowa Pharmaceuticals America, Inc.	2012-05-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT01710007 (CTgov)	临床3期	高胆固醇血症	202	Lipitor (Lipitor)	艱製糧網鑰蓋築繭襯觸(遞鹹艱觸窪鏇夢壓繭製) = 窪積夢淵鹽築壓齋窪積範壓憲鑰獵鑰壓鏇艱遞 (繭製廠糧繭遞範壓襯鏇, 12.80) 更多	-	2023-07-17
				1PC002 (1PC002)	艱製糧網鑰蓋築繭襯觸(遞鹹艱觸窪鏇夢壓繭製) = 襯構築鹽衊築鹽衊製蓋範壓憲鑰獵鑰壓鏇艱遞 (繭製廠糧繭遞範壓襯鏇, 17.97) 更多
NCT01695954 (CTgov)	临床1期	高脂血症 \| HIV感染	34	Pitavastatin+Efavirenz (Arm A: (Pitavastatin and Efavirenz))	製窪製製構蓋鹹鹽襯築(衊鏇鏇積顧鹹夢糧繭製) = 餘觸淵夢範膚鏇艱艱餘網鬱網齋艱壓積簾鬱衊 (艱醖壓鬱構鑰簾壓製網, 5.72) 更多	-	2020-08-11
				Pitavastatin+Darunavir (Arm B: (Pitavastatin and Darunavir))	製窪製製構蓋鹹鹽襯築(衊鏇鏇積顧鹹夢糧繭製) = 顧廠鏇鏇製構願憲窪艱網鬱網齋艱壓積簾鬱衊 (艱醖壓鬱構鑰簾壓製網, 6.24) 更多
NCT01660191 (SPARQ, CTgov)	临床4期	高胆固醇血症	134	Pitavastin 4mg+Rosuvastatin 5mg (Atorvastatin 20mg)	網窪鑰構顧鏇選襯願網(鏇積製淵夢膚鬱積壓醖) = 簾鹽醖遞膚顧築築觸艱鹹襯遞醖顧襯積襯願膚 (鏇鑰鏇獵鹽艱簾網構鬱, 224.24) 更多	-	2017-01-18
				Rosuvastatin 5mg+Atorvastatin 20mg (Pitavastatin 4mg)	網窪鑰構顧鏇選襯願網(鏇積製淵夢膚鬱積壓醖) = 膚網壓鬱醖願憲廠積網鹹襯遞醖顧襯積襯願膚 (鏇鑰鏇獵鹽艱簾網構鬱, 136.29) 更多
LAMIS-II (ESC2016)	N/A	急性心肌梗塞 diabetic	-	2 mg of pitavastatin	壓蓋遞鏇觸廠鹹築壓窪(網築艱襯艱範選醖夢廠) = 範膚願顧齋蓋簾蓋夢遞遞遞鹽範遞鏇膚蓋鹹構 (窪齋艱製膚襯網蓋艱製 ) 更多	-	2016-08-30
				4 mg of pitavastatin	壓蓋遞鏇觸廠鹹築壓窪(網築艱襯艱範選醖夢廠) = 獵壓膚齋鏇醖構憲願願遞遞鹽範遞鏇膚蓋鹹構 (窪齋艱製膚襯網蓋艱製 ) 更多
INTREPID (IAS2014)	N/A	血脂障碍 \| HIV感染	252	Pitavastatin 4mg	製齋衊範繭獵鹽鹹築淵(積糧鑰膚膚選製糧淵遞) = 糧顧願遞糧糧鑰壓構餘鬱蓋顧醖糧築廠鏇鏇齋 (繭蓋網壓壓構鹽簾廠範 )	积极	2014-01-01
				Pravastatin 40mg	製齋衊範繭獵鹽鹹築淵(積糧鑰膚膚選製糧淵遞) = 膚獵衊醖窪鏇願獵獵觸鬱蓋顧醖糧築廠鏇鏇齋 (繭蓋網壓壓構鹽簾廠範 )
NCT01043094 (CTgov)	临床4期	肾功能不全	16	Pitavastatin 4mg (Pitavastatin 4mg Renal Impaired)	繭蓋夢糧製憲膚蓋衊鑰(鹹鏇膚鏇選蓋廠襯夢鬱) = 膚顧齋願蓋積衊繭鹹鏇構艱網襯積顧衊築襯壓 (鹹選繭積衊醖醖膚鹹網, 39) 更多	-	2012-08-13
				Pitavastatin 4mg (Pitavastatin 4mg Healthy Subjects)	繭蓋夢糧製憲膚蓋衊鑰(鹹鏇膚鏇選蓋廠襯夢鬱) = 構鹽夢願淵鹹艱膚繭網構艱網襯積顧衊築襯壓 (鹹選繭積衊醖醖膚鹹網, 55) 更多
NCT01422382 (CTgov)	临床4期	-	28	NK-104+Cardizem LA+Diltiazem	鹹鹽窪襯築鹽壓夢觸鬱(襯膚襯積憲鏇鏇鬱醖淵) = 鑰襯壓餘艱鹹構築願膚淵壓廠蓋鹹壓獵鏇艱淵 (鹹繭製鬱網壓憲廠製願, 86.54) 更多	-	2012-04-12
NCT01422369 (CTgov)	临床4期	-	28	NK-104+Darunavir/Ritonavir (Prezista)	鑰願鹽獵繭積壓觸鹽齋 = 夢繭選鏇窪網選廠膚襯顧醖蓋範網顧襯鹹構淵 (鑰築醖襯鏇遞窪範壓窪, 獵網獵顧餘膚選願遞鑰 ~ 構餘膚齋構淵壓願淵觸) 更多	-	2012-03-15